Isobutyl-deoxynyboquinone (IB-DNQ) is a selective substrate for NAD(P)H:quinone oxidoreductase (NQO1). Isobutyl-deoxynyboquinone can be used for the research of anticancer[1].
Isobutyl-deoxynyboquinone (0.01~100 μM; OSCC cells) demonstrates greater cytotoxic potency against SCCF1 and SCCF2 cell lines, and less against the SCCF3 cell line. Isobutyl-deoxynyboquinone (0.1~3 μM; 60 minutes; SCCF1 cells) induces cytotoxicity in a dose-dependent manner[1].
Isobutyl-deoxynyboquinone (0.5~2 mg/kg; i.v.; 20 hours) achieves average peak plasma concentration levels. Isobutyl-deoxynyboquinone (1 mg/kg; p.o.; 4 hours) achieves peak plasma concentrations[1].
| Animal Model: | Cats |
| Dosage: | 0.5~2 mg/kg (Pharmacokinetic Analysis) |
| Administration: | I.v. |
| Result: | Achieved average peak plasma concentration levels. |
| Animal Model: | Cats |
| Dosage: | 1 mg/kg (Pharmacokinetic Analysis) |
| Administration: | P.o. |
| Result: | Achieved peak plasma concentration. |
[1]. Lundberg AP, et al. Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species. Invest New Drugs. 2017;35(2):134-144.